Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing psoriasis treatment in this IPC-led symposium at ICD 2025 in Rome.
Discover expert insights on a recent study analyzing the mental health outcomes of patients with moderate to severe psoriasis treated with bimekizumab in Phase 2/3 trials. This detailed commentary provides essential data on bimekizumab’s impact on mental health, enhancing the understanding of its safety and efficacy in psoriasis treatment.
Boehringer Ingelheim’s SPEVIGO® is now FDA-approved for generalized pustular psoriasis in adults and pediatric patients aged 12+, with expanded indications in China and approval in 48 countries.
UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the FDA, representing a major milestone in the treatment of adults with moderate to severe plaque psoriasis. Read more about this groundbreaking development.
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on the topline results from the EFFISAYIL™ 2 trial.
Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis and psoriatic arthritis.
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of Health, Labour, and Welfare.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
